Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc

Darius Armstrong-James; Justin Stebbing; Andrew Scourfield; Erasmus Smit; Bridget Ferns; Deenan Pillay; Mark Nelson

doi:10.1016/j.antiviral.2010.02.324

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc

Antiviral Res. 2010 May;86(2):224-6. doi: 10.1016/j.antiviral.2010.02.324. Epub 2010 Mar 6.

Authors

Darius Armstrong-James¹, Justin Stebbing, Andrew Scourfield, Erasmus Smit, Bridget Ferns, Deenan Pillay, Mark Nelson

Affiliation

¹ Imperial College, St. Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK.

PMID: 20211653
DOI: 10.1016/j.antiviral.2010.02.324

Abstract

Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection.

MeSH terms

Anti-HIV Agents / therapeutic use*
Cyclohexanes / therapeutic use*
Drug Resistance, Viral
Genotype
HIV Infections / drug therapy*
HIV Infections / virology*
HIV-2 / isolation & purification*
Humans
Maraviroc
Pyrrolidinones / therapeutic use*
RNA, Viral / genetics
Raltegravir Potassium
Treatment Outcome
Triazoles / therapeutic use*

Substances

Anti-HIV Agents
Cyclohexanes
Pyrrolidinones
RNA, Viral
Triazoles
Raltegravir Potassium
Maraviroc